Public Calendar: March 13-19, 2022
This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.
Official Name: Robert M. Califf, M.D., MACC, Commissioner of Food and Drugs
No Significant Event
Official Name: Janet Woodcock, M.D., Principal Deputy Commissioner
Event Date: 03/16/2022
Location: Washington, DC
Subject: Association of Clinical Research Organizations (ACRO's) 20th Anniversary; Discussion Panelist
FDA Participant/Group: RICHARDAE ARAOJO;
Non FDA Participant/Group: Representatives from industry, US and EU regulatory agencies, policy makers, patient groups, and other stakeholders
Official Name: Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affairs
No Significant Event
Official Name: Jim Sigg, Deputy Commissioner for Operations
No Significant Event
Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response
No Significant Event
Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy
Event Date: 03/18/2022
Location: Virtual
Subject: Review of Aspartame to be Conducted by the International Agency for Research on Cancer
FDA Participant/Group: ANNE KIRCHNER, RUSSSELL CAMPBELL, DANIEL FOLMER, PAUL HONIGFORT
Non FDA Participant/Group: Maia Jack (American Beverage Association); Kate Loatman (International Council of Beverages Association); Stuart Page (Polsinelli Law);
Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs
No Significant Event
Official Name: Erica Jefferson, Associate Commissioner for External Affairs
No Significant Event
Official Name: Jacqueline O'Shaughnessy, Acting Chief Scientist
No Significant Event
Official Name: Patrizia Cavazzoni, M.D., Director, Center for Drug Evaluation and Research
Event Date: 03/17/2022
Location: Virtual
Subject: Monthly COVID-19 Evidence Accelerator Therapeutics/Vaccines Lab Meeting
FDA Participant/Group: N/A
Non FDA Participant/Group: Representatives of the Foundation and Friends of Cancer Research
Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research
Event Date: 03/14/2022
Location: Virtual
Subject: Response Evaluation in Neurofibromatosis and Schwannomatosis Winter Meeting; Facilitating the Development of Gene Therapy for Conditions That Are Less Common
FDA Participant/Group: N/A
Non FDA Participant/Group: Attendees of Response Evaluation in Neurofibromatosis and Schwannomatosis Winter Meeting
Event Date: 03/17/2022
Location: Virtual
Subject: Immuno-Oncology 360° Conference; Recent Regulatory Developments for CAR-T Cells
FDA Participant/Group: N/A
Non FDA Participant/Group: Attendees of Immuno-Oncology 360° Conference
Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health
Event Date: 03/17/2022
Location: Virtual
Subject: Medical Device Updates
FDA Participant/Group: ELLEN FLANNERY; MELISSA TORRES; ARIEL SEELEY;
Non FDA Participant/Group: Philip Desjardins, Riley Swinehart, Robert Durgin (Johnson and Johnson);
Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition
No Significant Event
Official Name: Mitchell R. Zeller, J.D., Director, Center for Tobacco Products
Event Date: 03/15/2022
Location: Baltimore, MD
Subject: Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting; Panelist: Updates on the FDA Center for Tobacco Products
FDA Participant/Group: BENJAMIN APELBERG; KATHLEEN CROSBY;
Non FDA Participant/Group: Members of the Society for Research on Nicotine and Tobacco
Official Name: Steven Solomon, Director, Center for Veterinary Medicine
No Significant Event
Official Name: William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research
No Significant Event
Official Name: Mark Raza, J.D., Chief Counsel
No Significant Event